AGENDA
Caesars Palace, Las Vegas, Nevada, USA

Wednesday, February 24th

3:00-6:00 pm Registration desk open
6:30 pm Opening Dinner........................................................................................................Bradley Ogden Restaurant

Thursday, February 25th

6:30 am Registration desk open
7:00-8:00 am Breakfast........................................................................................................Octavius 5&6
8:00-8:15 Welcome: Leon and Debra Black, MRA Co-Founders.............................................Octavius 1-4
Introduction: Wendy KD Selig, MRA President and Chief Executive Officer

8:15-9:35 MRA award reports: Biological factors driving melanoma carcinogenesis
Session Chair: Boris Bastian, MD
8:15-8:35 The novel melanoma oncogene GNAQ provides new opportunities for therapeutic intervention:
Boris Bastian, MD, University of California, San Francisco
8:35-8:55 A genome-wide association study to identify melanoma predisposition genes:
Nicholas G Martin, PhD, Queensland Institute for Medical Research
8:55-9:15 Genetics of melanoma metastasis: Daniel Pinkel, PhD, University of California, San Francisco
9:15-9:35 Synthetic lethality to MAP kinase pathway inhibition in BRAF-mutant melanoma:
Levi Garraway, MD, PhD, Dana-Farber Cancer Institute

9:35-10:00 Regression of melanomas in patients by inhibiting activated BRAF with PLX4032
Paul Chapman, MD, Memorial Sloan-Kettering Cancer Center

10:00-10:15 Break

10:15-12:00 Leveraging technologies for improved cutaneous melanoma detection
Session Chair: Allan Halpern, MD
10:15-10:30 The challenge and promise of technologies for melanoma detection:
Allan Halpern, MD, Memorial Sloan-Kettering Cancer Center
10:30-11:20 Individual Technologies:
Computerized diagnostic system: Laura Korb Ferris, MD, PhD, University of Pittsburgh,
Electro-Optical Sciences
Genetic-based detection system: William Wachsman, MD, PhD, University of California,
San Diego / San Diego VA and Scientific Advisory Board, DermTech International
Remote sensing technology: Clara Curiel, MD, Arizona Cancer Center, Raytheon Company /
University of Arizona collaboration
Electronic biopsy: Ulrik Birgersson, SciBase AB
Real-time confocal microscopy: Kelly Nelson, MD, Duke University; Lucid
11:20-11:45 Perspective: Martin Weinstock, MD, PhD, Brown University and Rhode Island Hospital
11:45-12:00 Discussion and Q&A

12:00-1:30 Lunch.......................................................................................................................Octavius 5&6

1:30-2:50 MRA award reports: Advancing immunotherapeutic and surgical approaches for melanoma treatment
Session Chair: Victor Engelhard, PhD
1:30-1:50 MHC-associated phosphoepitopes as targets for melanoma immunotherapy:
Victor Engelhard, PhD, University of Virginia
1:50-2:10 Platform for MHC-exchange based T cell therapy for melanoma:
Ton Schumacher, PhD, The Netherlands Cancer Institute
2:10-2:30 Immunologic signatures of response to Ipilimumab:
Jedd Wolchok, MD, PhD, Memorial Sloan-Kettering Cancer Center
2:30-2:50 Surgery and immunotherapy for melanoma metastatic to distant sites:
Donald Morton, MD, John Wayne Cancer Institute

Accelerating the pace of scientific discovery
Thursday, February 25th (cont.)

2:50-3:40 MRA award reports: Featuring the 2008 Young Investigators
Session Chair: Laura Brockway-Lunardi, PhD, MRA Scientific Program Director

2:50-2:55 Introduction
2:55-3:10 Targeting CD4+ T cells for melanoma immunotherapy: Timothy Bullock, PhD, University of Virginia
3:10-3:25 Regulation of T cell chemokine receptor expression during vaccination: Tumor-targeted immunotherapy: David Mullins, PhD, University of Virginia
3:25-3:40 Defining the role of inducible co-stimulator (ICOS)-expressing T cells against melanoma: Padmanee Sharma, PhD, MD Anderson Cancer Center

3:40-4:00 Break

4:00-4:45 Nutrition and cancer - Approaches for melanoma research
David Heber, MD, PhD, University of California, Los Angeles

4:45-4:50 Summary: Suzanne Topalian, MD, MRA Chief Science Officer

5:30-8:00 pm Reception and Entertainment.................................................................Terrace and Octavius 1-4
Remarks by Mike Milken, FasterCures Chairman and MRA Board Member
Featuring a special performance by Australian popular vocal quartet, Human Nature

Dinner on your own

Friday, February 26th

6:30 am Registration desk open
7:00-8:00 am Breakfast.................................................................Octavius 5&6

8:00 am Introduction: Suzanne Topalian, MD.................................................................Octavius 1-4

8:05-9:45 MRA award reports: Targeting cellular and molecular pathways for melanoma therapeutics
Session Chair: Jonathan Cebon, MD

8:05-8:25 Therapeutic targeting of melanoma stem cells: Jonathan Cebon, MBBS, FRACP, MD, Ludwig Institute for Cancer Research, Melbourne Center for Clinical Sciences
8:25-8:45 Systemic MFG-E8 blockade as melanoma therapy: Glenn Dranoff, MD, Dana-Farber Cancer Institute
8:45-9:05 Accelerating melanoma therapy: Genomics, drug screening and informatics: Dave Hoon, PhD, John Wayne Cancer Institute
9:05-9:25 Therapeutic inhibition of mutant activated signaling pathways in melanoma: Neal Rosen, MD, PhD, Memorial Sloan-Kettering Cancer Center
9:25-9:45 A pathway to rational combination therapies for melanoma: Synthetic lethal screening with small molecule inhibitors, guided by phosphoproteome analysis: Michael Weber, PhD, University of Virginia

9:45-10:15 Mapping the melanoma genome - Current knowledge and future directions towards prevention and treatment
Lynda Chin, MD, Dana-Farber Cancer Institute

10:15-10:30 Break

10:30-12:00 Developing experimental drug combinations - Opportunities and challenges
Session Co-chairs: Drew Pardoll, MD, PhD, Johns Hopkins University and Rachel Humphrey, MD, Bristol-Myers Squibb
Panelists:
David Bonk, Esq, Bristol-Myers Squibb
Kathleen Dohoney, PhD, Novartis Institutes for BioMedical Research, Inc.
James Doroshow, MD, U.S. National Cancer Institute
Mark Ratain, MD, University of Chicago

12:00 Concluding remarks: Wendy Selig
12:00 pm Lunch (available for carry-out).................................................................Octavius 5&6